Shares of Shilpa Medicare Ltd were trading almost 5% higher on 15 May after the company secured an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA).

Shilpa Medicare’s subsidiary, Shilpa Pharma Lifesciences, Unit-1, acquired EIR from the US FDA, and the location is classified as VAI.  The USFDA conducted an inspection at unit-1 between 3 and 7 March 2025.

Earlier this month, the company’s biologics unit, Shilpa Biologics in Dharwad, Karnataka, got European GMP accreditation for manufacturing test batches based on an examination conducted by the competent body of Austria from 18 February to 20 March 2025. The inspection concluded with zero observations.

Shilpa Biologicals signed a binding term contract with Switzerland’s mAbTree Biologics AG in March to develop, manufacture, market, and sell a new biological entity (NBE).

At 12:33 pm, the shares of Shilpa Medicare were trading 2.45% higher at Rs 711.90 on NSE.

Wondering About Shilpa Medicare Ltd? The Analyst Has Answers.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!